Search

Murine monoclonal antibodies (Mab) generated against human tumor antigens (Koprowski and Steplewski 1982) have renewed scientific and clinical interest in passive immunotherapy of human cancer (Kennett et aL 1980). Treatment of B cell leukemias with Mab, for instance, results in immediate reduction of leukemic cells in circulation (Levy and Miller 1983; Ritz et al. 1981). A Mab (17–1A) against an antigen of gastrointestinal cancers (Herlyn et al. 1979) was found to suppress the growth of human tumors in nude mice (Herlyn et al. 1980) and produced significant improvement in the clinical status of a number of patients with metastatic disease (Koprowski 1984a; Sears etal. 1984). As expected, most patients injected with this Mab produced antibody against the murine immunoglobulin (Ig) but, more germaine to this forum, a significant proportion of this antibody was directed against the antigen binding or idiotypic (Id) portion of the molecule (anti-Id) (Koprowski et al. 1984).